Abstract
Pancreatic cancer has one of the poorest prognoses among all cancers partly because of its silent nature and tendency for late discovery but also because of its persistent resistance to chemotherapy. At present there are very limited treatment alternatives for pancreatic cancer, hence the need to develop novel and more efficient drugs. It is well known that mutations in K-Ras oncogene accumulate early in the disease progression and occur in almost all of pancreatic ductal adenocarcinomas (PDAC). A key downstream target of the Ras family is phosphoinositide 3-kinase (PI3K), the enzyme responsible for generation of 3-phosphorylated phosphoinositides and activation of Akt (Protein Kinase B/Akt). The PI3K/Akt pathway is involved in inhibition of apoptosis and stimulation of cell proliferation and it has been estimated that at least 50% of all cancer types are related to deregulation of this signalling pathway. In this review we will discuss how the PI3K/Akt/mTOR signalling network is altered in pancreatic cancer and further give an overview of preclinical and clinical studies where this pathway has been targeted.
Keywords: Akt, drug treatment, K-Ras, Mtor, pancreatic cancer, pancreatic ductal adenocarcinoma, phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeting Phosphoinositide 3-Kinase Pathways in Pancreatic Cancer – from Molecular Signalling to Clinical Trials
Volume: 11 Issue: 5
Author(s): Marco Falasca, Federico Selvaggi, Richard Buus, Sara Sulpizio and Charlotte E. Edling
Affiliation:
Keywords: Akt, drug treatment, K-Ras, Mtor, pancreatic cancer, pancreatic ductal adenocarcinoma, phosphatidylinositol 3-kinase
Abstract: Pancreatic cancer has one of the poorest prognoses among all cancers partly because of its silent nature and tendency for late discovery but also because of its persistent resistance to chemotherapy. At present there are very limited treatment alternatives for pancreatic cancer, hence the need to develop novel and more efficient drugs. It is well known that mutations in K-Ras oncogene accumulate early in the disease progression and occur in almost all of pancreatic ductal adenocarcinomas (PDAC). A key downstream target of the Ras family is phosphoinositide 3-kinase (PI3K), the enzyme responsible for generation of 3-phosphorylated phosphoinositides and activation of Akt (Protein Kinase B/Akt). The PI3K/Akt pathway is involved in inhibition of apoptosis and stimulation of cell proliferation and it has been estimated that at least 50% of all cancer types are related to deregulation of this signalling pathway. In this review we will discuss how the PI3K/Akt/mTOR signalling network is altered in pancreatic cancer and further give an overview of preclinical and clinical studies where this pathway has been targeted.
Export Options
About this article
Cite this article as:
Falasca Marco, Selvaggi Federico, Buus Richard, Sulpizio Sara and E. Edling Charlotte, Targeting Phosphoinositide 3-Kinase Pathways in Pancreatic Cancer – from Molecular Signalling to Clinical Trials, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/187152011795677382
DOI https://dx.doi.org/10.2174/187152011795677382 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Systems Pharmacokinetic and Pharmacodynamic Approach to Identify Opportunities and Pitfalls in Energy Stress-Mediated Chemoprevention: The Use of Metformin and Other Biguanides
Current Drug Targets The Role of Inflammatory Response in Stroke Associated Programmed Cell Death
Current Neuropharmacology Recent Advance in the Pharmacology of Dihydropyrimidinone
Mini-Reviews in Medicinal Chemistry Vitamin D Analogs as Anti-Carcinogenic Agents
Anti-Cancer Agents in Medicinal Chemistry A Review on Important Histone Acetyltransferase (HAT) Enzymes as Targets for Cancer Therapy
Current Cancer Therapy Reviews Peptides As Therapeutics with Enhanced Bioactivity
Current Medicinal Chemistry Synthesis of Sulfur Containing Colchicine Derivatives and their Biological Evaluation as Cytotoxic Agents
Letters in Drug Design & Discovery Novel Sample Preparation for Mass Spectral Analysis of Complex Biological Samples
Current Proteomics Full Factorial Experimental Design for Development and Validation of a RP-HPLC Method for Estimation of Letrozole in Nanoformulations
Current Pharmaceutical Analysis Pharmacology and Clinical Effect of Platonin, a Cyanine Photosensitizing Dye: Potential Molecular Targets
Current Pharmaceutical Biotechnology Pulmonary Drug Delivery: A Role for Polymeric Nanoparticles?
Current Topics in Medicinal Chemistry The Glutathione System as an Attractive Therapeutic Target
Drug Design Reviews - Online (Discontinued) Chemically Synthesized Matrix Metalloproteinase and Angiogenesis-inhibiting Peptides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Meet Our Section Editor
Technology Transfer and Entrepreneurship (Discontinued) Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins
Current Organic Chemistry Pharmacogenomics of Breast Cancer Targeted Therapy: Focus on Recent Patents
Recent Patents on DNA & Gene Sequences New Trends in Molecular Imaging of Tumor Angiogenesis
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Current Vascular Pharmacology Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions
Current Cancer Drug Targets Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry